Clinical trial · Observational
Collection of Gastrointestinal Malignant and Non-malignant Human Samples
NCT03415919CI-TRIAL-00052299unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To collect human tissue, blood, and fecal samples from patients suffering from Inflammatory Bowel Disease and Colorectal Cancer. The samples will be used to establish biomimetic human organ-on-a-chip technology, as well as study the role of the microbiome in the pathogenesis in human gastrointestinal diseases.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colo-rectal Cancer | — | UNRESOLVED | — |
| Inflammatory Bowel Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no intervention will be given to patients. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- IBD patients
- description
- Patients suffering from IBD scheduled to have a biopsy by colonoscopy.
- interventionNames
- Other: no intervention will be given to patients.
- label
- CRC patients
- description
- Patients suffering from CRC scheduled to have a biopsy by colonoscopy, or surgical resection of colon.
- interventionNames
- Other: no intervention will be given to patients.
- label
- Control patients
- description
- Patients who are scheduled to have a colonoscopy for routine screening to serve as a control population.
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy-proven colorectal cancer scheduled to have surgical resection of primary site, at participating and approved facilities. Since it is standard clinical care to resect certain suspicious gastrointestinal masses without a pre-existing biopsy, patients who are undergoing resections for highly suspicious masses believed to be cancer, may be consented. * Diagnosed with Inflammatory Bowel Disease (IBD) or Crohn's Disease (CD), scheduled to have biopsy and/or fecal collection. * scheduled to have a colonoscopy as part of routine screening. * 18 years old. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * The study will not exclude potential subjects from participation on the basis of ethnic origin or gender. Subjects recruited will include men, women, and all ethnic origins, provided they meet all inclusion criteria listed above.
References
Publications (0)
Data not yet available
No reference posted for this study.